TOS

Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis

LEVERKUSEN, Germany - Biofrontera AG (DSE: B8F) announces todaythat it has received very positive results in the dose finding partof its phase IIb/III clinical trial started in autumn 2006. BF-200ALA, a gel that combines the active substance 5-aminolevulinic acid(ALA) with the nanoemulsion BF-200, was strongly and significantlysuperior to placebo in the treatment of actinic keratosis. BF-...

Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis

SCHLIEREN (Zurich), Switzerland, July 3, 2007 - Cytos BiotechnologyAG (SWX:CYTN) announced today results from a phase IIa study withCYT003-QbG10 in atopic dermatitis. CYT003-QbG10 is animmunotherapeutic product candidate currently in development forthe treatment of allergic diseases. The present study aimed toassess safety, tolerability and exploratory efficacy of the productcandidate in a...

New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging

Women Report Partner's Symptoms Negatively Affect Relationship BOCA RATON, Fla., June 25, 2007 /PRNewswire/ -- Results of a newnationwide survey show that more than half of women whose malepartners have symptoms of a medical condition known as lowtestosterone incorrectly attribute them to the normal course ofaging. The survey also found that, while women believe their malepartner's sympto...

Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus

-LymphoStat-B(R) significantly reduced signs and symptoms of SLEdisease at 52 Weeks and demonstrated durable clinical andbiological activity at 76 weeks- ROCKVILLE, Md., June 14, 2007 /PRNewswire-FirstCall/ -- HumanGenome Sciences, Inc. today announced the presentation of Phase 2trial data demonstrating that LymphoStat-B(R) (belimumab)significantly reduced disease activity across multiple...

Vision Deficit in Retinitis Pigmentosa Mice Corrected with DNA Nanoparticles

CLEVELAND--(BUSINESS WIRE)--Jun 4, 2007 - Copernicus Therapeutics,Inc. announced today that a research team at University of OklahomaHealth Sciences Center, led by Dr. Muna Naash, Professor of CellBiology, demonstrated that Copernicus' DNA nanoparticles correctedvision defects in a mouse model of retinitis pigmentosa (RP). Thesefindings were presented at the American Society of Gene Therapy...

Diatos Announces Positive Clinical Results for its DTS-201 Doxorubicin Prodrug Program

PARIS--(BUSINESS WIRE)--Jun 4, 2007 - Diatos SA, an internationalbiopharmaceutical company focusing on the research, development andcommercialization of targeted anti-cancer drugs, today announcedthat they presented data from a Phase I clinical trial of theiranti-cancer compound, DTS-201, at the 43rd Annual Meeting of theAmerican Society of Clinical Oncology (ASCO) in Chicago, USA. DTS-20...

Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for the Treatment of Psoriasis

Schlieren (Zurich), Switzerland, May 24, 2007 - CytosBiotechnology AG (SWX:CYTN) reported today results from aplacebo-controlled, double-blind combined phase I/IIa study withCYT007-TNFQb, a novel vaccine candidate for the treatment ofpsoriasis and other inflammatory conditions. The present study wasa first-time-in-man clinical trial and included 48 patientssuffering from moderate to seve...

Auxilium Announces New Data That Show Total Testosterone Blood Levels Increase Significantly Following Switch from AndroGel(R) to Testim(R)

MALVERN, Pa., May 22, 2007 /PRNewswire-FirstCall/ -- AuxiliumPharmaceuticals, Inc. today announced that new data showimprovements in symptoms of decreased libido, energy levels anderectile function in 76 percent of hypogonadal men after switchingbrands of testosterone replacement gel therapy. Total testosteronelevels increased significantly in patients who switched toAuxilium's Testim(R)...

Ad hoc: Interim report about clinical trial of BF-200 ALA in actinic keratosis

LEVERKUSEN, Germany, 30 April 2007 - Biofrontera AG announcedthat an interim report regarding the clinical study of BF-200 ALAin actinic keratosis was received today from an independent reviewcommittee. The objectives of the study are to investigate theefficacy and safety of several doses of BF-200 ALA in photodynamictherapy. The comments received today refer to the clinical resultseight...